US FDA extends review for saxagliptin in diabetes
This article was originally published in Scrip
Executive Summary
The US FDA has extended the PDUFA date of Bristol-Myers Squibb/AstraZeneca's investigational type 2 diabetes treatment Onglyza (saxagliptin), a DPP-4 inhibitor, by three months to July 30th.